Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,775 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.
Pasquau J, Hidalgo-Tenorio C, Montes ML, Romero-Palacios A, Vergas J, Sanjoaquín I, Hernández-Quero J, Aguirrebengoa K, Orihuela F, Imaz A, Ríos-Villegas MJ, Flores J, Fariñas MC, Vázquez P, Galindo MJ, García-Mercé I, Lozano F, de Los Santos I, de Jesus SE, García-Vallecillos C; QoLKAMON STUDY GROUP. Pasquau J, et al. Among authors: flores j. PLoS One. 2018 Apr 12;13(4):e0195068. doi: 10.1371/journal.pone.0195068. eCollection 2018. PLoS One. 2018. PMID: 29649309 Free PMC article. Clinical Trial.
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D, Imaz A, Perez I, Viciana P, Valencia E, Curto J, Martín T, Castaño M, Rojas J, Espinosa N, Moreno V, Asensi V, Iribarren JA, Clotet B, Force L, Bachiller P, Knobel H, López Bernaldo De Quirós JC, Blanco JR, Rozas N, Vergas J, Ocampo A, Camacho A, Flores J, Gomez-Sirvent JL; KIDAR Study Group. Podzamczer D, et al. Among authors: flores j. J Antimicrob Chemother. 2014 Sep;69(9):2536-40. doi: 10.1093/jac/dku157. Epub 2014 May 15. J Antimicrob Chemother. 2014. PMID: 24833755
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R; PROTEST study group. Poveda E, et al. Among authors: flores j. HIV Med. 2017 Aug;18(7):482-489. doi: 10.1111/hiv.12479. Epub 2016 Dec 30. HIV Med. 2017. PMID: 28035758 Free article. Clinical Trial.
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Berenguer J, Pérez-Elías MJ, Bellón JM, Knobel H, Rivas-González P, Gatell JM, Miguélez M, Hernández-Quero J, Flores J, Soriano V, Santos I, Podzamczer D, Sala M, Camba M, Resino S; Spanish Abacavir, Lamivudine, and Zidovudine Cohort Study Group. Berenguer J, et al. Among authors: flores j. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):154-9. doi: 10.1097/01.qai.0000194231.08207.8a. J Acquir Immune Defic Syndr. 2006. PMID: 16394846
Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.
Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A, Paredes R. Garcia F, et al. Among authors: flores j. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19520. doi: 10.7448/IAS.17.4.19520. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394029 Free PMC article.
Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study.
Minguez C, Ortega E, Flores J, Carmena J, Masiá M, Montero M, Reus S, Tornero C, Galindo MJ, Garcia-Deltoro M, Amador C, Cuadrado JM, Usó J, López-Aldeguer J. Minguez C, et al. Among authors: flores j. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19634. doi: 10.7448/IAS.17.4.19634. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394138 Free PMC article.
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J; NODy Study Group. Podzamczer D, et al. Among authors: flores j. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):390-6. doi: 10.1097/QAI.0b013e318198a0cc. J Acquir Immune Defic Syndr. 2009. PMID: 19214120 Clinical Trial.
[Spanish recommendations for proper use of enfuvirtide].
Ribera E, Moreno S, Viciana P, Echevarría S, Flores J, Francés A, Gómez-Sirvent JL, González J, Hernández-Quero J, Lozano F, Mallolas J, Muñoz A, Ocampo A, Portilla J, Pulido F, Rivero A, Santos J, Soriano V, Antela A, Arazo P, Arribas JR, Cervantes M, Domingo P. Ribera E, et al. Among authors: flores j. Enferm Infecc Microbiol Clin. 2007 Feb;25(2):131-42. doi: 10.1157/13098573. Enferm Infecc Microbiol Clin. 2007. PMID: 17288910 Review. Spanish.
Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Rubio R, Serrano O, Carmena J, Asensi V, Echevarría S, Flores J, Ribera E, Zarraga M, Ocampo A, de la Fuente B, Sepúlveda MA, Mariño AI, Minguez C, Vicent R, Cartón JA, Moyano B, Esteban H, Mahillo B, Serrano L, González-García J; GESIDA 44/04 SIMPATAZ Study Group. Rubio R, et al. Among authors: flores j. HIV Med. 2010 Oct 1;11(9):545-53. doi: 10.1111/j.1468-1293.2010.00827.x. Epub 2010 Mar 19. HIV Med. 2010. PMID: 20345884 Free article.
1,775 results